Study Results & Research Projects

Summaries & Associations of Study Results

TR-453 Nickel Subsulfide

Print this page Easy Link

http://ntp.niehs.nih.gov/go/8684

Target Organs and Levels of Evidence
NTP Technical Report Number 453

Produced from Chemtrack Database 09/19/01

CHEMICAL/ CAS NUMBER PEER REVIEW DATE PRIMARY USES ROUTE/EXPOSURE LEVELS STUDY LABORATORY
NICKEL SUBSULFIDE
12035-72-2 		11/29/94 MAJOR COMPONENT IN NICKEL REFINERY FLUE DUST. NOT USED COMMERCIALLY IN U.S. (TDB) Inhalation R: 0, 0.075, OR 0.15 M: 0, 0.6, OR 1.2 MG/M3; 50/GROUP Lovelace Inhal Tox Res Inst (DOE)
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM):
MR: CLEAR EVIDENCE LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 0/53 3/53 6/53; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 3/53 6/53; ALVEOLAR/BRONCHIOLAR ADENOMA OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 6/53 11/53
ADRENAL GLAND MEDULLA: PHEOCHROMOCYTOMA 13/53 30/52 38/53 OR MALIGNANT PHEOCHROMOCYTOMA 0/53 2/52 10/53 COMBINED 14/53 30/52 38/53
NON-NEOPLASTIC LESIONS: LUNG: CHRONIC ACTIVE INFLAMMATION; FOCAL ALVEOLAR EPITHELIAL HYPERPLASIA; MACROPHAGE HYPERPLASIA; FIBROSIS
NASAL CAVITY: CHRONIC ACTIVE INFLAMMATION; OLFACTORY EPITHELIAL ATROPHY
FR: CLEAR EVIDENCE LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 2/53 5/53 5/53 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/53 3/53 6/53 OR SQUAMOUS CELL CARCINOMA 0/53 1/53 0/53 COMBINED 2/53 6/53 9/53
ADRENAL GLAND MEDULLA: PHEOCHROMOCYTOMA 2/53 7/53 36/53
NON-NEOPLASTIC LESIONS: LUNG: CHRONIC ACTIVE INFLAMMATION; FOCAL ALVEOLAR EPITHELIAL HYPERPLASIA; MACROPHAGE HYPERPLASIA; FIBROSIS
NASAL CAVITY: CHRONIC ACTIVE INFLAMMATION; OLFACTORY EPITHELIAL ATROPHY
ADRENAL GLAND: (MEDULLA) HYPERPLASIA
MM: NO EVIDENCE
NON-NEOPLASTIC LESIONS: LUNG: CHRONIC ACTIVE INFLAMMATION; BRONCHIALIZATION; MACROPHAGE HYPERPLASIA; FIBROSIS
NASAL CAVITY: ACUTE INFLAMMATION; OLFACTORY EPITHELIAL ATROPHY
FM: NO EVIDENCE
NON-NEOPLASTIC LESIONS: LUNG: CHRONIC ACTIVE INFLAMMATION; BRONCHIALIZATION; MACROPHAGE HYPERPLASIA; FIBROSIS
NASAL CAVITY: ACUTE INFLAMMATION; OLFACTORY EPITHELIAL ATROPHY

Back to top

Web page last updated on February 10, 2006